angelini pharma to acquire catalyst pharmaceuticals for 41 billion usd 35 billion euros entering the us market and consolidating its leadership in brain health and rare disease

WB_1331_HEALTH_TECHNOLOGIESWB_1350_PHARMACEUTICALSWB_621_HEALTH_NUTRITION_AND_POPULATIONTAX_DISEASE_DISEASES

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.